title: Promoting remyelination in multiple sclerosis: current drugs and future prospects.
abstract: Myelin destruction due to inflammatory oligodendrocyte cell damage or death in conjunction with axonal degeneration are among the major histopathological hallmarks of multiple sclerosis (MS). The majority of available immunomodulatory medications for MS are approved for relapsing-remitting (RR) MS, for which they reduce relapse rate, MRI measures of inflammation, and the accumulation of disability. These medications are, however, of little benefit during progressive MS where axonal degeneration following demyelination outweighs inflammation. This has sparked great interest in the development of new remyelination therapies aimed at reversing the neurodegenerative damage observed in this disease. Remyelination as a result of oligodendrocyte production from oligodendrocyte precursor cells (OPCs) is considered a promising potential target for the treatment of all stages of MS. In this review we present an overview of a) approved medications (some of them FDA-and EMA-approved for other diseases) with a proposed role in regeneration, b) regenerative treatments under investigation in clinical trials, and c) promising future therapeutic approaches aiming specifically at facilitating endogenous repair.
authors.affiliation: Department of Neurology, Medical Faculty, University of Düsseldorf, Germany/Department of Neurosciences, Lerner Research Institute, USA.
authors.forename: David
authors.initials: D
authors.lastname: Kremer
authors.affiliation: Department of Neurology, Medical Faculty, University of Düsseldorf, Germany.
authors.forename: Patrick
authors.initials: P
authors.lastname: Küry
authors.affiliation: Department of Neurosciences, Lerner Research Institute, USA duttar@ccf.org.
authors.forename: Ranjan
authors.initials: R
authors.lastname: Dutta
mesh_terms: D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology*; D009186:Myelin Sheath / Q000187:drug effects* / Q000473:pathology; D009416:Nerve Regeneration / Q000187:drug effects; D009836:Oligodendroglia
keywords: Multiple sclerosis; remyelination; therapy; trials